Pepsinogen C is an aspartyl-proteinase usually involved in the digestion of proteins in the stomach, and an androgen- inducible protein in breast cancer cells. In this study we evaluated its expression and clinical significance in patients with resectable pancreatic cancer. Pepsinogen C expression was examined by immunohistochemical methods in a series of 73 pancreatic carcinomas. The prognostic value of pepsinogen C was retrospectively evaluated by multivariate analysis. A total of 21 (28.8%) pancreatic carcinomas stained positively for pepsinogen C. The percentage of pepsinogen C-positive tumors was significantly higher in well-differentiated tumors (38.3%) than in moderately differentiated (15.8%) and poorly differentiated (0%) tumors (p<0.05). In addition, statistical analysis revealed that pepsinogen C expression was associated with clinical outcome. Thus, patients with pepsinogen C-negative tumors have a poorer overall survival than those with pepsinogen C-positive tumors. Our results led us to consider that the expression of pepsinogen C may represent a useful biological marker in pancreatic cancer. Expression of this protein may be a marker of gastric-type differentiation of the tumors and it might also reflect the existence of a complete hormone receptor pathway in a subset of pancreatic carcinomas.
BlackR.J., BrayF., FerlayJ., ParkinD.M.Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.Eur J Cancer1997; 33: 1075–107.
FoltmannB., JensenA.L.Human progastricsin. Analysis of intermediates during activation into gastricsin and determination of the amino acid sequence of the propart.Eur J Biochem1982; 128: 63–70.
5.
TangJ., WongR.N.S.Evolution in the structure and function of aspartic proteases.J Cell Biochem1987; 33: 53–63.
6.
SamloffI.M., LiebmanW.M.Cellular localization of the group II pepsinogens in human stomach and duodenum by inmunofluorescence.Gastroenterology1973; 65: 36–42.
7.
ReidW.A., VongsorasakL., VallerM.J., KayJ.Identification of the acid proteinase in human seminal fluid as a gastricsin originating in the prostate.Cell Tissue Res1984; 236: 597–600.
8.
ReeseJ.H., McNealJ.E., RedwineE.A., SamloffI.M., StameyT.A.Differential distribution of pepsinogen II between the zones of the human prostate and the seminal vesicle.J Urol1986; 136: 1148–52.
9.
SánchezL.M., FreijeJ.M.P., MerinoA.M., VizosoF., FoltmannB., López-OtínC.Isolation and characterization of a pepsin C zymogen produced by human breast tissues.J Biol Chem1992; 267: 24725–31.
10.
MerinoA.M., VázquezJ., RodríguezJ.C.Pepsinogen C expression in tumors of extragastric origen.Int J Biol Markers2000; 15: 165–70.
11.
TentiP., AguzziA., RivaC. Ovarian mucinous tumors frequently express makers of gastric, intestinal, and pancreatobiliary epithelial cells.Cancer1992; 69: 2131–42.
12.
KonishiN., NakaokaS., MatsumotoK. Expression of pepsinogen II with androgen and oestrogen receptors in human prostate carcinoma.Pathol Int1999; 49: 203–7.
13.
Díez-ItzaY., MerinoA.M., ToliviaJ., VizosoF., SánchezL.M., López-OtínC.Expression of pepsinogen C in human breast tumors and correlation with clinicopathologic parameters.Br J Cancer1993; 68: 637–40.
14.
VizosoF., SánchezL.M., Díez-ItzaI., MerinoA.M., López-OtínC.Pepsinogen C is a new prognostic marker in primary breast cancer.J Clin Oncol1995; 13: 54–61.
15.
ScorilasA., DiamandisE.P., LevesqueMA. Immunoenzymatically determined pepsinogen C concentration in breast cytosols: an independent favourable prognostic factor in node-positive patients.Clin Cancer Res1999; 5: 1778–85.
16.
GottesmanM.The role of proteases in cancer.Semin Cancer Biol1990; 1: 97–160.
17.
LiottaL.A., Stetler-StevensonW.G.Tumor invasion and metastasis: an imbalance of positive and negative regulation.Cancer Res1991; 51(Suppl): 5054–9.
18.
BalbínM., López-OtínC.Hormonal regulation of the human pepsinogen C gene in breast cancer cells.J Biol Chem1996; 271: 15175–81.
19.
SessaF., BonatoM., FrigerioB., CapellaC., SolciaE., PratM.Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells.Gastroenterol1990; 98: 1655–65.
20.
BonatoM., SessaF., CapellaC.Relationship between expression of gastrointestinal markers and survival in human pancreatic carcinoma.Pancreas1994; 787–91.
KloppelG., LingenthalG., Von BulowM., KernH.F.Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: Studies in xenografted tumors and clinicohistopathologic correlation in a series of 75 cases.Histopathology1985; 9: 841–6.
23.
VaitukaitisJ.L.Production of antisera with small doses of immunogen: multiple intradermal injections.Methods Enzymol1981; 73: 46–52.
24.
HollandeE., Trocheris de St-FrontV., Louet-HermitteP.Differentiation features of human pancreatic tumor cells maintained in nude mice and in culture: immunocytochemical and ultrastructural studies.Int J Cancer1984; 34: 177–85.
25.
AzumaT., HiraiM., ItoS.Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report.Int J Cancer1996; 67: 492–7.
26.
GreenwayB.A.Carcinoma of the exocrine pancreas: a sex hormone responsive tumour?Br J Surg1987; 74: 441–2.
27.
LhosteE.F., RoebuckB.D., Brinck-JohnsenT., LongneckerD.S.Effect of castration and hormone replacement on azasarine-induced pancreatic carcinogenesis in male and female Fisher rats.Carcinogenesis1987; 8: 699–703.
28.
SumiC., LongneckerD.S., RoebuckB.D., Brinck-JohnsenT.Inhibitory effects of estrogen and castration on the early stage pancreatic carcinogenesis in Fisher rats treated with azaserine.Cancer Res1989; 49: 2332–6.
29.
MelvinW.S., BorosL.G., MuscarellaP.Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo.Surgery1997; 121: 392–7.
30.
MuscarellaP., BorosL.G., FisherW.E., RinkC., MelvinW.S.Oral dehydroepiandrosterone inhibits the growth of human pancreatic cancer in nude mice.J Surg Res1998; 79: 154–7.
31.
KeatingJ.J., JohnsonP.J., CochraneA.M.A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma.Br J Cancer1989; 60: 789–92.
32.
TaylorO.M., BensonE.A., Mc MahonM.J.Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group.Br J Surg1993; 80: 384–6.
33.
WongA., ChanA.Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study.Cancer1993; 71: 2200–3.
34.
GreenwayB.A.Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trial.BMJ1998; 316: 1935–8.
35.
CorbishleyT., IqbalM.J., WilkinsonM.L., WilliamsR.Androgen receptor in human normal and malignant pancreatic tissue and cell lines.Cancer1986; 57: 1992–5.
36.
TargaronaE.M., PonsM.D., GlezG.Is exocrine pancreatic cancer a hormone dependent tumor?Hepatogastroenterol1991; 38: 165–9.
37.
SinghS., BakerP.R., PoulsomR., WrightN.A., SheppardM.C., LangmanM.J.S., NeoptolemosJ.P.Expression of oestrogen receptor and oestrogen-inducible genes in pancreatic cancer.Br J Surg1997; 84: 1085–9.
